Ocugen
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 65
- Market Cap
- $382.8M
- Website
- http://www.ocugen.com
- Introduction
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Expanded Access Program for RP in Adults
- Conditions
- Retinitis Pigmentosa
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Ocugen
- Registration Number
- NCT06574997
- Locations
- ๐บ๐ธ
Associated Retina Consultants, Phoenix, Arizona, United States
๐บ๐ธAdvanced Research, Deerfield Beach, Florida, United States
๐บ๐ธErie Retina Research, Erie, Pennsylvania, United States
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
- Conditions
- Retinitis Pigmentosa
- Interventions
- Genetic: Sub-Retinal Administration of OCU400-301
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 150
- Registration Number
- NCT06388200
- Locations
- ๐บ๐ธ
Advanced Research, LLC., Deerfield Beach, Florida, United States
๐บ๐ธBascom Palmer Eye Institute, University of Miami, Miller School of Medicine, Miami, Florida, United States
๐จ๐ฆCalgary Retina Consultants, Calgary, Alberta, Canada
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
- Conditions
- Geographic Atrophy
- Interventions
- Genetic: OCU410
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 60
- Registration Number
- NCT06018558
- Locations
- ๐บ๐ธ
Advanced Research, LLC, Coral Springs, Florida, United States
๐บ๐ธThe Retina Institute, Saint Louis, Missouri, United States
๐บ๐ธValley retina Institute, McAllen, Texas, United States
Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease
- Conditions
- Stargardt Disease
- Interventions
- Genetic: OCU410ST
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 42
- Registration Number
- NCT05956626
- Locations
- ๐บ๐ธ
Mississippi Retina Associates, Jackson, Mississippi, United States
๐บ๐ธRetina Foundation of the Southwest, Dallas, Texas, United States
๐บ๐ธBascom Palmer Eye Institute, Miami, Florida, United States
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
- Conditions
- Center Involved Diabetic Macular EdemaDiabetic Macular Edema
- Interventions
- Drug: OCU200 Low DoseDrug: OCU200 Medium DoseDrug: OCU200 High Dose
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 28
- Registration Number
- NCT05802329
- Locations
- ๐บ๐ธ
Advanced Research LLC, Deerfield Beach, Florida, United States
๐บ๐ธErie Retina Research, LLC, Erie, Pennsylvania, United States
๐บ๐ธRetina Consultants of Texas Research Centers, Bellaire, Texas, United States
Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXINโข (BBV152) in Adults Aged 18 Years and Older
- Conditions
- COVID-19
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Ocugen
- Registration Number
- NCT05541289
- Locations
- ๐บ๐ธ
Woods, Langhorne, Pennsylvania, United States
Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults
- Conditions
- COVID-19
- Interventions
- Biological: BBV152
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 400
- Registration Number
- NCT05258669
- Locations
- ๐บ๐ธ
Voyage Medical, Tempe, Arizona, United States
๐บ๐ธClinical Site Partners, Winter Park, Florida, United States
๐บ๐ธPalm Springs Community Health Center, Miami Lakes, Florida, United States
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
- Conditions
- Retinitis PigmentosaLeber Congenital Amaurosis
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 124
- Registration Number
- NCT05203939
- Locations
- ๐บ๐ธ
Associated Retina Consultants, Phoenix, Arizona, United States
๐บ๐ธOcugen Site 5 - University of California, San Diego (UCSD) - Shiley Eye Institute, La Jolla, California, United States
๐บ๐ธOcugen Site 3 - Bascom Palmer Eye Institute, Miami, Florida, United States
Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 252
- Registration Number
- NCT03785340
- Locations
- ๐บ๐ธ
Ophthalmology Associates, Saint Louis, Missouri, United States
๐บ๐ธMartel Medical Eye Group, Rancho Cordova, California, United States
๐บ๐ธRand Eye Institute, Pompano Beach, Florida, United States
Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
- Conditions
- oGVHDOcular Graft vs Host DiseaseLubricant Eye DropsGraft Versus Host DiseaseOphthalmic SolutionsOcular Surface DiseaseBrimonidine TartrateGraft vs Host Disease
- Interventions
- Drug: Placebos
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 59
- Registration Number
- NCT03591874
- Locations
- ๐บ๐ธ
Emory Eye Center, Atlanta, Georgia, United States
๐บ๐ธOhio State University, Columbus, Ohio, United States
๐บ๐ธUniversity of Penn Scheie Eye Institute,, Philadelphia, Pennsylvania, United States